Rifaximin Therapy of Irritable Bowel Syndrome

Clinical Medicine Insights: Gastroenterology

Review

Saman Sabounchi¹  Hoonmo L. Koo²  Herbert L. Dupont³  David B. Huang⁴ 

[1] Baylor College of Medicine, Houston, TX.;Baylor College of Medicine, Houston, TX.;University of Texas at Houston School of Public Health, Houston, TX.;Baylor College of Medicine, Houston, TX.;University of Texas at Houston School of Public Health, Houston, TX.;St. Luke's Episcopal Hospital.;Veterans Affairs Medical Center, East Orange, NJ.;

关键词: rifaximin;    irritable bowel syndrome;    small intestinal bacterial overgrowth;   

DOI  :  10.4137/CGast.S7382

来源: Sage Journals

【 摘 要 】

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of specific organic pathology. Although the underlying pathogenesis of IBS is not well-understood, small intestinal bacterial overgrowth (SIBO) or other abnormalities in the gut flora is believed to contribute to the development of a subset of IBS cases. Rifaximin is a poorly absorbed antimicrobial with activity against enteric pathogens. A number of studies have shown a significant improvement in IBS symptoms with antibiotic therapy including rifaximin. In this review, we discuss the pharmacokinetics, in vitro susceptibility profile, and efficacy and safety data from clinical trials of rifaximin treatment of IBS.

【 授权许可】

CC BY-NC   
© 2012 SAGE Publications.

【 图 表 】

Figure 2.

Figure 11.